Publications by authors named "Bronislav Janek"
Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates.
Methods: This single-center cohort study aims to determine the effectiveness of our standardized risk-stratified pretransplant cardiovascular screening protocol, which includes coronary angiography (CAG), in identifying advanced CVD, the proper pretransplant management of which could lead to a reduction in the incidence of major cardiac events (MACE) in the early posttransplant period.
Treatment of Takotsubo cardiomyopathy (TC) with left ventricular outflow obstruction (LVOTO) remains challenging. Mechanical circulatory support (MCS) as a bridge to myocardial recovery is sometimes the only therapeutic option, even though the optimal type of MCS is still under debate. This report describes a case of TC complicated by cardiogenic shock due to LVOTO and severe mitral regurgitation that was successfully treated with the latest generation percutaneous pump Impella CP®.
View Article and Find Full Text PDFObjectives: The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patient population.
Methods: Patient-level data from two all-comers observational studies (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled and analyzed in terms of their primary endpoint.
Article Synopsis
- The study evaluated the safety and effectiveness of ultrathin strut polymer-free sirolimus-eluting stents (PF-SES) in a diverse patient population undergoing percutaneous coronary interventions (PCI).
- A total of 7243 patients were included, showing a low target lesion revascularization (TLR) rate of 2.2% and a stent thrombosis rate of 0.7% over 9-12 months of follow-up.
- The results indicate that PF-SES are safe and effective, with particularly high procedural success rates in challenging cases like in-stent restenosis and isolated left main coronary artery disease.
Article Synopsis
- The study aimed to evaluate regional and ethnic differences in patients treated with polymer-free sirolimus-eluting stents (PF-SES) across Asia and Europe.
- It combined data from two observational studies, analyzing 7243 patients and focusing on target lesion revascularization (TLR) rates and major cardiovascular events (MACE) over 9-12 months.
- Results showed low TLR (2.2%) and MACE (4.4%) rates across regions, with notably longer dual antiplatelet therapy (DAPT) in Asia compared to Europe, indicating that longer DAPT may lead to even lower clinical event rates.
Objectives: The aim of this registry was to evaluate the clinical efficacy and safety of the Coroflex Blue cobalt-chromium stent in real-world practice.
Background: The development of cobalt-chromium bare-metal stents (BMS) with thinner struts has lead to better deliverability and lower target-lesion revascularization rates compared with stainless steel BMS.
Methods: The Coroflex Blue Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease attributable to single de novo or restenotic nonstented lesions of a single vessel amenable for percutaneous stenting.
Orthotopic heart transplantation (OHTx) represents a well established method of end-stage heart failure treatment. Allograft coronary artery disease (CAD) still remains to be one of the most important limiting factors for OHTx recipients' long-term survival. Unfortunately, allograft CAD can be detected very early after OHTx.
View Article and Find Full Text PDF